Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
“Currently, there are 127 drugs for Alzheimer’s disease in clinical trials; three of these have proven to be promising — donanemab, remternetug, and blarcamesine).”
https://healthnews.com/health-conditions/alzheimers-dementia/why-uk-health-regulator-is-rejecting-lecanemab-under-nhs/
14 months (EMA) v 12 months (FDA)
Look at every approved AD drug. It appreciates by $10-$20 billion upon announcement of approval.
Too bad you can not admit why you are here...to gain information to aid you in making decisions on your investment. That is why every single person is here...especially when Anavex didn't provide the half-ass information that it provides now. So, people were here to get any scrap of info. The craved the warrior princess's every stupid post and every post of wisdom from you, and George was their God...every person here had made a decision based on what they read here. People who say they don't...are the biggest liars aroind.
It is for all those people he duped. You sound like a pretentious prick. Enjoy hell!
George 8 years ago was like the best infomercial ever...everyone ate his every word. They begged him for responses and links.
A very simple and easy to follow TA:
Just using 2 reference points, one can see the downtrend from $7.50 there were 3 hits establishing the visible level of resistance, so that level must be broken to change the trend ($6.20 to $6.30)....above that level the change goes from down to up.
Additionally, the 200 day SMA offers another important level of support which is currently at $5.43 (plus or minus).
Resistance is $6.20 to $6.30
https://finviz.com/quote.ashx?t=AVXL&ty=c&ta=1&p=d
Support is $5.43 (give or take)
Oh yeah, news would be great but is not used by people who follow trends with price and volume as a key indicator justifying momentum (or a reason to hop on the train),,,
The EMA process doesn't move as fast as you are projecting. Be aware that the timelines given by the EMA are in working days, not calendar days. So the usual time frame for EMA approval ranges from 391 to 460 days. The EMA does have an accelerated assessment process but that still is150 days plus clock stops with and average of 222 days.
The FDA is on average about 9 to 10 months unless it has fast track designation, then it is closer to 6 months. So if the MAA and the NDA are both submitted by EOY then the FDA approval would come first.
by then we’ll also have a really good idea if 3.71 works for schizophrenia, and “if” it does, wow!! Double whammy!!
We're still 24-36 months away from the sort of share price appreciation many here are waiting for. It sounds dreadful but that's the unfortunate reality barring a full-on buyout vs. what I expect to be a limited partnership. It's a longer growth strategy but if successful, will reward long-term investors significantly more than the fast cash options.
December '2024: EMA submission
May '25: EMA approval
June '25: Production begins
It'll require at least 4 or 5 quarters for Blarcamesine to hit its stride. Look at almost every blockbuster drug's annual revenue and you will see that it takes a while before peak revenue occurs. Financial analysts also want at least a year's worth of data to form accurate cash flow models. The stock simply cannot hit its max share price without giving these underlying factors some time to unfold.
That's how I estimate June 2026 as the earliest we can see Anavex start to untap its potential. By then, we'll know if it works. If after a year people who are taking it are showing signs of stabilization or improvement, demand will jump greatly. If after a year something better comes along and knocks Blarcamesine off its perch, that is also a possibility. Let's wait for the cash flow models to form a consensus. It'll take some time but I think it'll be worth the wait, if it's true that the EMA is "pulling" Anavex for a submission.
Thanks for keeping an eye on the MJFF’s newsport Talon. All I saw as I read was FDA blah blah FDA blah blah blah……! This imo is the hold up that everyone keeps complaining about that we are waiting for.
On that note as I was listening to an interview with Dr. Jack Kruse where he mentioned and confirmed that its pretty normal for those companies or individuals that are a threat to BP to have their literature “held up” or completely rejected in the peer reviewed process.
George’s prognostications mean zilch . I put him on ignore long time ago . He cried wolf one too many times
Last week Georgejjl emphatically told us to expect HUGE NEWS this Thursday, September 26, 2024.
Stand by.
“...In late summer 2024, the U.S. Food and Drug Administration (FDA) issued a “Letter of Support” to encourage drug developers to use the alpha-synuclein seed amplification assay (aSyn-SAA) — a Parkinson’s biomarker discovered in 2023 — in research and clinical trials. Because the tool can objectively detect early biology related to Parkinson’s and related diseases, including Dementia with Lewy Bodies (DLB), even before any symptoms emerge, trials using aSyn-SAA are better positioned to test therapies that aim to delay or even prevent the onset of disease, which could speed drug trials and improve their chances of success….”
FDA Encourages Use of Parkinson's Biomarker for Future Clinical Trials
https://www.michaeljfox.org/news/fda-encourages-use-parkinsons-biomarker-future-clinical-trials?em_cid=mc-a1bVL000002LLrV
Thank you Talon38
Good luck and GOD bless,
You totally missed the grammar lesson explaining the hesitation of many here to accept your analysis.
Had nothing to do with the analysis itself.
TA requires a dedication I do not have, but the “encouragement” was for a centering effort which is possible. AROUND just won’t do it.
TGD plans to wait another year or more to sell the biomarker test on Amazon. Recently, he's been considering opening a store on Amazon to generate extra revenue for shareholders.
It would seem to be partly the case, this was part of what someone reported from the AGM -
"When asked about delays with PD/PDD, he answered strongly that major advances were being made in PD biomarkers, and testing doesn’t just come off the shelf at ‘Amazon’ as he put it, they are being developed, and thus they are waiting because they feel they can run a more effective trial with them. He used the 2b/3 AD trial as an example, suggesting at the time they initiated that trial, the biomarkers they were testing for were not at all common then, but are now common in most AD trials. His comments seem to be pointing toward the new alpha-synuclein biomarker discovered by the Michael J Fox foundation last year."
Perhaps Anavex was waiting for this before starting its PD trial.
Via MJFF, a new more focused plan for Parkinson's from their work with the FDA. Will it help AVXL?
https://www.michaeljfox.org/news/fda-encourages-use-parkinsons-biomarker-future-clinical-trials?em_cid=mc-a1bVL000002LLrV
" SP going forward will be news driven."---we supposed to get some "NEWS" ???? Not from Anavex----WTF !!!!!!! Can someone on this board tell us when "real" news is coming !!!!!!!
There won't be any news because of "EMBARGO", Clown's favorite word. There is a reason why he like to attends these conference with same old shitty data.
Hi Tom; I believe the SP going forward will be news driven.
You cherry picked a snippet of my analysis, which rarely helps any conversation about a complex picture, but in good humor we can make light of things. However, what I think I was describing was a central area, a magnetic hub, an inflection point, and price jiggered around this very area today, to highlight my vision. 😛 so now, we are looking at a pennant , looking upward isn't it? Price is "supposed to" launch upward from this triangle terminal. But the target zone has resistance from 6.00 and up. The Fib tool aligns with the recent pivots, to indicate a "top target zone" 6.80 to 7.10 area. 7.00, and 6.50/6.60 area are all targets I'm watching. A bounce here could be just a 50 cent move to hit 6.00/6.20, also a fib target, and get sold right there. A more bullish rally would be looking to continue a few days or few weeks to the 6.50- 7.00 target area. If we still have weeks and months to wait for major bullish news, then I would feel cautious watching any rally reach the 6.60- 7.00 area.
Personally, my bias remains neutral but looking for the next selling attack to try bleeding price back down to the 5.00 and even into the 4.80/4.70 target zone, maybe October. A slow stretch looking like sideways, that bleeds and tumbles into late October. For bargains to buy again around 4.90. What rally we get now, from 5.50 to 6.20 maybe 6.50.... could get hammered down, in the typical AVXL pattern... while we wait and wait, and wait for the rest of the year. Long time frame to watch. 🎱🫡🫣🥱
I don’t know what “normal” volume means on your planet but the average daily volume in AVXL is 986,660. Today’s volume was 418,847. That’s 56.53% lower than the average daily volume. Safe to say today’s volume was not higher than normal. In fact, the volume was pretty light. With the stock bobbing up and down aimlessly on low volume, there is clearly no investor expectation of HUGE NEWS on Thursday.
And by the way, predicting that the stock will close higher on an up day with 45 minutes to the close isn’t exactly remarkable.
AVXL stock was near the high of the day and the closing volume was indeed higher than normal.
Good luck and GOD bless,
Contrary to George's statement. Today looks to be about the LOWEST VOLUME I have ever seen. 280K shares with 20minutes till the bell.
John k9uwa
I think you mean “pretend” to own other stocks that he can be assigned to bash.
You do realize you are allowed to sell and buy other stocks instead?
Another lie. You have no shame.
You must be as excited as they are. Up 8 pennies.
It's green. Sheesh.
Expect AVXL to close at or near the high of the day on higher than normal volume.
Good luck and GOD bless,
Here comes the end of day selloff. Each and every day. Will this stock ALWAYS be a POS?
Check YOUR cookies.
Much more likely "link" issue.
Same as Sarasota so no different Season to us.
Do notice the breeze of the Atlantic is much more of influence
than the bath water Gulf differential.
Grease Trap on the outdoor grill.
I'll make a plaque.
Agree about Sarasota. We are midstate 170' above Sea Level. I have a "Rule" re: Grass and Snow. I didn't put it there I am not moving it!! Landlords we are. 14 homes. 2 to live in and a dozen rentals zero mort's. Haven't been in snow for over 20 years. Don't enjoy watching it on TeeVee. As to George I don't think posters pay much attention. Any new posters would read many more postings than just George's. Enough to get the idea that George is wrong most of the time.
John k9uwa
SAVA recovered all yesterday's loss but this POS has no volume. Hope this don't become next BIVI.
AVXL up a whopping 10 cents on anticipation of HUGE NEWS on Thursday, September 26, 2024.
Anyone notice that for a fair few months if you put "Anavex" into google and filter by last 24 hours it often comes up with the EMA page and sometimes FDA from the last few hours?
There is nothing actually on there about anavex if you click (at-least that is publicly viewable) but it would seem perhaps it's on their system somewhere and in some form getting refreshed or something which might cause this? I don't seem to notice it for other drug stocks if I filter by last 24 hours.
What? You don't consider a cat 3 seasonal?
Ahh how wonderful it is to be free to make our own mistakes.
Just don't go around flaunting about them.
I suspect nobody cares but is nice to know I hold small spot in that house....
Fool me once shame on you.
Fool me twice.....
Do you really imagine any serious money inflow to AVXL stock
based upon a first impression of George?
Followers
|
1086
|
Posters
|
|
Posts (Today)
|
16
|
Posts (Total)
|
470131
|
Created
|
12/18/07
|
Type
|
Free
|
Moderators RedShoulder Steady_T Bourbon_on_my_cornflakes kund mike_dotcom nidan7500 |
Anavex®Life Sciences Corp. (the “Company”) is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including drug candidates to treat Alzheimer’s disease, other central nervous system (“CNS”) diseases, pain and various types of cancer. The Company’s lead compound ANAVEX®2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome.
Anavex®Life Sciences’ lead drug candidate, ANAVEX®2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex® a research grant to develop ANAVEX®2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX®2-73 into a Parkinson’s disease clinical trial. ANAVEX®3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions.
The Company is in preparation for ANAVEX®2-73 for a Phase 2/3, placebo-controlled trial in Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX®2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease.
Headquartered in New York, Anavex® Life Sciences is an American publicly traded corporation on Nasdaq quoted as AVXL
.Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |